Revolution Medicines, Inc. Stock Price, News & Analysis

Revolution Medicines, a clinical-stage oncology company focused on targeted therapies for RAS-addicted cancers, will feature CEO Mark A. Goldsmith in a fireside chat at the 22nd Annual Needham Healthcare Conference from April 17-20, 2023. The chat is scheduled for 3:00 p.m. Eastern on April 20, 2023, and will be held virtually with a webcast available. Interested parties can access the live presentation and the subsequent replay on the company’s website for at least 14 days after the event.

The company specializes in developing RAS(ON) Inhibitors aimed at various oncogenic RAS protein variants, with RMC-6236 and RMC-6291 currently in clinical development. Additional pipeline candidates target other RAS mutations and include RAS Companion Inhibitors for combination therapies. For further details, visit Revolution Medicines Events.

Revolution Medicines, Inc. (Nasdaq: RVMD) announced it will present significant preclinical data at the AACR Annual Meeting 2023, taking place from April 14-19, 2023, in Orlando, Florida. Notable presentations include the discovery of RMC-6291, a tri-complex KRAS G12C inhibitor, and RMC-9805, a first-in-class mutant-selective KRAS G12D inhibitor that synergizes with immunotherapy in preclinical models. These innovations aim to address RAS-addicted cancers, showcasing the company's commitment to developing targeted oncological therapies. The presentations are scheduled for April 16 and 17, highlighting advancements in cancer treatment that could significantly impact future clinical strategies.

Revolution Medicines, Inc. (Nasdaq: RVMD) has successfully closed an underwritten public offering, raising $345 million by selling 15,681,818 shares of common stock at a price of $22.00 per share. The underwriters fully exercised their option to purchase additional shares, contributing 2,045,454 shares to the total. The offering was managed by J.P. Morgan, TD Cowen, SVB Securities, and Guggenheim Securities. The registration statement was filed on March 2, 2021, and this transaction is crucial for funding the company's research and development of targeted therapies for RAS-addicted cancers.

Revolution Medicines has announced a public offering of 13,636,364 shares of common stock at $22.00 each, aiming to raise approximately $300 million. All shares are offered by the company, with an additional option for underwriters to purchase up to 2,045,454 shares within 30 days. The offering is expected to close on March 7, 2023. J.P. Morgan, TD Cowen, SVB Securities, and Guggenheim Securities are the joint book-running managers. The funds will support ongoing developments in targeted therapies for RAS-addicted cancers, part of Revolution Medicines' R&D pipeline.

Revolution Medicines, Inc. (Nasdaq: RVMD) has initiated an underwritten public offering to sell up to $300 million of its common stock. The offering includes a 30-day option for underwriters to purchase an additional $45 million worth of shares. The offering is subject to market conditions and might not be completed as proposed. J.P. Morgan, TD Cowen, SVB Securities, and Guggenheim Securities are the joint book-running managers for this offering. The company focuses on developing targeted therapies for RAS-addicted cancers, with a robust R&D pipeline centered on RAS(ON) and Companion Inhibitors.

Revolution Medicines (RVMD) reported Q4 2022 financial results, revealing total revenue of $15.3 million versus $9.5 million YoY, primarily from collaboration with Sanofi. This increase was partly due to a non-cash $7.6 million revenue adjustment following the termination of the Sanofi agreement. R&D expenses surged to $66.1 million, reflecting higher clinical trial costs for new drugs RMC-6236 and RMC-6291. The company recorded a net loss of $56.5 million for the quarter. Looking ahead, RVMD anticipates a net loss of $335 to $365 million for 2023. Its pipeline includes several promising RAS(ON) Inhibitors with clinical advancements expected in 2023.

Revolution Medicines, Inc. (Nasdaq: RVMD) announced it will report its fourth quarter and full year 2022 financial results on February 27, 2023, after market close. Senior management will discuss these results and corporate progress during a webcast at 4:30 p.m. Eastern Time. The company is focused on developing targeted therapies for RAS-addicted cancers, with key products in clinical development, including RMC-6236 and RMC-6291. The webcast will also be available as an archived session on its website for at least 14 days.